Movement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation

Market Focus07-16 10:28

On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.

On the news front, the company announced on July 15 that preliminary positive results from an investigator-initiated clinical trial of Kelimei (Satricabtagene Autoleucel) for post-adjuvant consolidation therapy in gastric/gastroesophageal junction adenocarcinoma have been accepted for poster presentation at the European Society for Medical Oncology Annual Meeting. The abstract is scheduled for publication on October 19 on the ESMO website.

Since enrollment began in May of last year, all participants who received Kelimei treatment have shown no post-surgical recurrence or metastasis. Kelimei is the world's first approved CAR-T cell therapy product for solid tumors, having received NMPA approval in June for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. This exploration into post-surgical consolidation therapy further expands the product's indication potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143100649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143100649","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation","media":"Market Focus","content":"<p><p>On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.</p><p>On the news front, the company announced on July 15 that preliminary positive results from an investigator-initiated clinical trial of Kelimei (Satricabtagene Autoleucel) for post-adjuvant consolidation therapy in gastric/gastroesophageal junction adenocarcinoma have been accepted for poster presentation at the European Society for Medical Oncology Annual Meeting. The abstract is scheduled for publication on October 19 on the ESMO website.</p><p>Since enrollment began in May of last year, all participants who received Kelimei treatment have shown no post-surgical recurrence or metastasis. Kelimei is the world's first approved CAR-T cell therapy product for solid tumors, having received NMPA approval in June for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. This exploration into post-surgical consolidation therapy further expands the product's indication potential.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.</p><p>On the news front, the company announced on July 15 that preliminary positive results from an investigator-initiated clinical trial of Kelimei (Satricabtagene Autoleucel) for post-adjuvant consolidation therapy in gastric/gastroesophageal junction adenocarcinoma have been accepted for poster presentation at the European Society for Medical Oncology Annual Meeting. The abstract is scheduled for publication on October 19 on the ESMO website.</p><p>Since enrollment began in May of last year, all participants who received Kelimei treatment have shown no post-surgical recurrence or metastasis. Kelimei is the world's first approved CAR-T cell therapy product for solid tumors, having received NMPA approval in June for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. This exploration into post-surgical consolidation therapy further expands the product's indication potential.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1143100649","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143100649","pubTimestamp":1784168890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.On the news front, the company announced on July 15 that preliminary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"走势提醒|CARsgen Therapeutics-B常规交易大涨5.51%，可立美术后巩固疗法获ESMO海报展示受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On July 16, CARsgen Therapeutics-B rose 5.51% in regular trading, trading at HK$16.89/share, with turnover of HK$29.95 million.On the news front, the company announced on July 15 that preliminary positive results from an investigator-initiated clinical trial of Kelimei (Satricabtagene Autoleucel) for post-adjuvant consolidation therapy in gastric/gastroesophageal junction adenocarcinoma have been accepted for poster presentation at the European Society for Medical Oncology Annual Meeting. The abstract is scheduled for publication on October 19 on the ESMO website.Since enrollment began in May of last year, all participants who received Kelimei treatment have shown no post-surgical recurrence or metastasis. Kelimei is the world's first approved CAR-T cell therapy product for solid tumors, having received NMPA approval in June for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. This exploration into post-surgical consolidation therapy further expands the product's indication potential.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143100649","isCrawlerRequest":true}